66 documents

Read All
01:29 , Dec 23, 2017 |  BioCentury  |  Regulation

Prioritizing preferences

The realization that patients have distinct preferences about the trade-offs and risks inherent in medical decisions -- and that their choices are frequently different from those physicians or regulators would make -- has mobilized FDA,...
Read More
22:21 , Oct 12, 2017 |  BC Innovations  |  Targets & Mechanisms

Mining the negatives

By investigating why its discontinued siRNA candidate against hepatitis B caused only weak responses in certain patients, Arrowhead Pharmaceuticals Inc. has upended a dogma about the virus’ genetics that has been clouding drug design and...
Read More
16:22 , Aug 31, 2017 |  BC Innovations  |  Translation in Brief

Extinguishing aversion

Last month in the Journal of Neuroscience, a team from the Chinese Academy of Sciences showed activating RAC1 could help treat opioid addiction by extinguishing the aversive memories of withdrawal that cause relapse in some...
Read More
20:57 , Feb 9, 2017 |  BC Innovations  |  Finance

PPP decline

BioCentury’s sixth annual analysis of public-private partnerships (PPPs) shows the lowest number of new alliances in 2016 since tracking began. The decline is a stark contrast to the enthusiasm of 2012, suggesting partners are becoming...
Read More
21:55 , Jan 20, 2017 |  BC Week In Review  |  Company News

Heat, Shattuck deal

Heat granted newco Shattuck an exclusive license to Heat technology, which Shattuck will use to develop its agonist redirected checkpoint (ARC) platform technology. The technology blocks checkpoint molecules and stimulates tumor necrosis factor (TNF) superfamily...
Read More
22:20 , Jan 6, 2017 |  BioCentury  |  Finance

Tiers of disappointment

A bad year for biotech was closed with an even worse 4Q16 as volatility ahead of the U.S. elections and continued concerns around drug pricing held every market cap band in the red despite a...
Read More
00:06 , Dec 8, 2016 |  BC Extra  |  Politics & Policy

ARC submits amyloidosis draft guidance to FDA

The Amyloidosis Research Consortium said it submitted draft guidance to FDA addressing drug development and clinical trial design for amyloid light chain (AL) amyloidosis. The patient group met with FDA, industry stakeholders and disease experts...
Read More
00:35 , Nov 30, 2016 |  BC Extra  |  Company News

Arrowhead prunes pipeline over toxicity concerns

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) sank $2.63 (60%) to $1.76 in early after-hours trading after it said will discontinue development of all programs using its EX1 liver-targeted, IV delivery vehicle for its RNA therapies. The cuts...
Read More
21:22 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

ARC-520: Ph IIb hold

Arrowhead said FDA placed a clinical hold on the double-blind, placebo-controlled, U.S. Phase IIb Heparc-2004 trial of IV ARC-520. Arrowhead said FDA placed the hold after deaths occurred in a non-human primate toxicology study in...
Read More
23:27 , Nov 9, 2016 |  BC Extra  |  Clinical News

Clinical hold for Arrowhead's HBV therapy

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) fell $1.91 (31%) to $4.20 on Wednesday after it said FDA placed a clinical hold on the Phase IIb Heparc-2004 trial of short interfering RNA therapy ARC-520 to treat HBV. The trial...
Read More